Project
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Ongoing - recruitment closed · 2021 until 2030
Silzle Tobias, Driessen Christoph, Fehr Martin, Hitz Felicitas, Lehmann Thomas
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2021
End Date
2030
Financing
Others
Study Design
Phase III
Keywords
MDS, lower risk, Imetelstat, anemia, transfusion-dependency
Labels
other tumors
Brief description/objective
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment